Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019

We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Murphy N, Shah P, Shih A, Khalili H, Liew A, Zhu X, Lee A Abstract Single-cell sequencing (SCS) is a powerful new tool that applies Next Generation Sequencing at the cellular level. SCS has revolutionized our understanding of tumor heterogeneity and the tumor microenvironment, immune infiltration, cancer stem cells (CSCs), circulating tumor cells (CTCs), and clonal evolution. The following chapter highlights the current literature on SCS in genitourinary (GU) malignancies and discusses future applications of SCS technology. The renal cell carcinoma (RCC) section highlights the use of SCS in characterizing ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Conclusions: Pretreatment De Ritis ratio was a significant predictor for OS, CSS, PFS and BRFS in urological cancers, indicating that it could be a promising prognostic factor during clinical practice.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
varam To elucidate the role of immune cell infiltration as a prognostic signature in solid tumors, we analyzed immune-function-related genes from four publicly available single-cell RNA-Seq data sets and twenty bulk tumor RNA-Seq data sets from The Cancer Genome Atlas (TCGA). Unsupervised clustering of pan-cancer transcriptomic signature showed two major immune function types: one related to NK-, T-, and B-cell functions and the other related to monocyte, macrophage, dendritic cell, and Toll-like receptor functions. Kaplan–Meier analysis showed differential prognosis of these two groups, dependent on the canc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractMuscle-invasive bladder cancer (MIBC) is a common malignancy of urinary system cancers, accounting for about 1/3 of all newly diagnosed bladder cancer cases. Due to its strong metastasis, the 5-year survival of MIBC is less than 50%, and in serious cases, the overall survival of metastatic bladder cancer patients is about 1.3  years. LncRNAs, a type of non-coding RNAs defined as the transcripts exceeding 200 nucleotides in length, are frequently aberrant in multiple cancers including cervical, ovarian, breast and bladder cancers. Recently, LUCAT1 (short for lung cancer-associated transcript 1), a lncRNA first ...
Source: Journal of Molecular Histology - Category: Laboratory Medicine Source Type: research
A. Calin Available systemic treatment options for cancers of the genitourinary system have experienced great progress in the last decade. However, a large proportion of patients eventually develop resistance to treatment, resulting in disease progression and shorter overall survival. Biomarkers indicating the increasing resistance to cancer therapies are yet to enter clinical routine. Long non-coding RNAs (lncRNA) are non-protein coding RNA transcripts longer than 200 nucleotides that exert multiple types of regulatory functions of all known cellular processes. Increasing evidence supports the role of lncRNAs in cance...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Kidney cancer is the third most diagnosed genitourinary malignancy in the world, after prostate and bladder cancer. In 2018, more than 400,000 new cases were diagnosed, causing 175,000 deaths.(1) Renal cell carcinoma (RCC) comprises more than 90% of such malignancies, primarily clear cell (70%) and papillary (10 –15%) histologic types.(2) Overall, nearly a half of the diagnoses were performed in low- and middle income countries (LMs) in 2018, where mortality due to RCC was 60%. The prognosis for a patient with RCC in LMs is poorer than in high- income settings (HICs), related to untimely recognition of sy mptoms, fra...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
Abstract In various cancers, high-grade tumor and poor survival rate in patients with upregulated lncRNAs UCA1 have been confirmed. Urothelial carcinoma associated 1 (UCA1) is an oncogenic non-coding RNA with a length of more than 200 nucleotides. The UCA1 regulate critical biological processes that are involved in cancer progression, including cancer cell growth, invasion, migration, metastasis, and angiogenesis. So It should not surprise that UCA1 overexpresses in variety of cancers type, including pancreatic cancer, ovarian cancer, gastric cancer, colorectal cancer, breast cancer, prostate cancer, endometrial c...
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer. Aging (Albany NY). 2020 Jun 13;12: Authors: Jin D, Zhang R, Chen H, Li C Abstract Bladder cancer (BC) is the most common malignancy of the urinary tract. We developed a new and ELISA kit for detecting aberrantly glycosylated integrin α3β1 (AG31) in human urine. We analysed urine samples (n=408) of patients with BC, renal cell carcinoma (RCC), prostate cancer (PC), cystitis, nephritis, and prostatitis from two centres in China. The subjects in the validation groups (n=2317) wer...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Purpose of review Systemic treatment of advanced urogenital malignancies has changed significantly in recent years and it will continue to change rapidly in upcoming years. It is the scope of this review article to providing the reader with the most recently approved treatment strategies to be used in daily routine for the individualized and most optimal treatment of our patients. Recent findings Immunooncological therapy (IOT) has emerged as the treatment of choice in metastatic renal cell carcinoma and we describe the most relevant clinical trials and we will give some differential therapeutic recommendation who mig...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: NOVEL THERAPIES FOR ADVANCED UROLOGIC CANCERS: Edited by Shahrokh F. Shariat Source Type: research
Publication date: September 2020Source: Urology Case Reports, Volume 32Author(s): Chawin Sukapiriya, Chanyoot Bandidwattanawong
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Neoadjuvant Therapy | Renal Cell Carcinoma | Toxicology | Urology & Nephrology